Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Cancer epigenetics

Reading the future of leukaemia

The identification of the regulatory protein ENL as essential to an aggressive form of leukaemia provides insight into transcriptional regulation and highlights potential avenues for therapy. See Letters p.265 & p.270

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: The protein ENL is crucial for MLL-rearranged leukaemia.


  1. See all news & views


  1. Biondi, A., Cimino, G., Pieters, R. & Pui, C.-H. Blood 96, 24–33 (2000).

    CAS  PubMed  Google Scholar 

  2. Erb, M. A. et al. Nature 543, 270–274 (2017).

    Article  ADS  CAS  Google Scholar 

  3. Wan, L. et al. Nature 543, 265–269 (2017).

    Article  ADS  CAS  Google Scholar 

  4. Li, Y. et al. Cell 159, 558–571 (2014).

    Article  CAS  Google Scholar 

  5. Meyer, C. et al. Leukemia 20, 777–784 (2006).

    Article  CAS  Google Scholar 

  6. Smith, E., Lin, C. & Shilatifard, A. Genes Dev. 25, 661–672 (2011).

    Article  CAS  Google Scholar 

  7. Chen, C.-W. & Armstrong, S. A. Exp. Hematol. 43, 673–684 (2015).

    Article  CAS  Google Scholar 

  8. He, N. et al. Proc. Natl Acad. Sci. USA 108, E636–E645 (2011).

    Article  CAS  Google Scholar 

  9. Okada, Y. et al. Cell 121, 167–178 (2005).

    Article  CAS  Google Scholar 

  10. Daigle, S. R. et al. Cancer Cell 20, 53–65 (2011).

    Article  CAS  Google Scholar 

  11. Bernt, K. M. et al. Cancer Cell 20, 66–78 (2011).

    Article  CAS  Google Scholar 

  12. Deshpande, A. J. et al. Cancer Cell 26, 896–908 (2014).

    Article  CAS  Google Scholar 

  13. Chen, S. et al. Mol. Cell 60, 319–327 (2015).

    Article  CAS  Google Scholar 

  14. Vlaming, H. & van Leeuwen, F. Chromosoma 125, 593–605 (2016).

    Article  CAS  Google Scholar 

  15. Patel, D. J. & Wang, Z. Annu. Rev. Biochem. 82, 81–118 (2013).

    Article  CAS  Google Scholar 

  16. Nicodeme, E. et al. Nature 468, 1119–1123 (2010).

    Article  ADS  CAS  Google Scholar 

  17. Filippakopoulos, P. et al. Nature 468, 1067–1073 (2010).

    Article  ADS  CAS  Google Scholar 

  18. Jang, M. K. et al. Mol. Cell 19, 523–534 (2005).

    Article  CAS  Google Scholar 

  19. Li, Y. et al. Mol. Cell 62, 181–193 (2016).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Or Gozani.

Ethics declarations

Competing interests

O.G. is a co-founder of EpiCypher, Inc. and Athelas Therapeutics, Inc.

Related links

Related links

Related links in Nature Research

Cancer: Bet on drug resistance

Drug discovery: Reader's block

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wilkinson, A., Gozani, O. Reading the future of leukaemia. Nature 543, 186–187 (2017).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer